Q3 2025 Earnings Call Transcript August 13, 2025 Organigram Global Inc. misses on earnings expectations. Reported EPS is ...

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market ...

Organigram's Q3 sales rose 72% to $51.14 million, driven by Motif acquisition and global demand, with margin gains and positive cash flow expected.

Analysts expect OrganiGram Holdings to report an earnings per share (EPS) of $-0.01. The announcement from OrganiGram Holdings is eagerly anticipated, with investors seeking news of surpassing ...

OrganiGram (OGI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.02 per share a year ago. These figures are ...

Organigram is a licensed cannabis producer based in Moncton, New Brunswick. It partnered with British American Tobacco in 2023 to develop new cannabis products and also bought The Edibles and ...

TORONTO, February 04, 2025--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of ...

Accelerates Organigram’s R&D and product pipeline development, provides meaningful capital injection of ~C$221 million and strengthens Organigram’s ability to compete in existing markets and ...

OrganiGram’s revenue growth is very impressive. With plenty of cash in hand, in my view, the company’s acquisitions and further product development will likely serve as revenue catalysts.

Organigram Maintains Strong Cash Position Prior to the Equity Top-Up, Organigram e njoyed a strong cash position of CA$168 million reported as at the end of Fiscal Q1-2022 (November 30, 2021).

Organigram still has up to $100.6 million worth of biological assets and inventory on its balance sheet. Given current trends, investors should expect writedowns going forward.

It was May 21, 2019 when OrganiGram first began trading on the Nasdaq. Since then the stock has lost more than 80% of its value -- by comparison, the Marijuana Life Sciences ETF has fallen by 71%.